FMCT-pc1.

We are funding a preclinical study aimed at optimizing combinations of metabolic therapies to treat metastatic cancer. In general, this treatment modality, called the “press pulse” strategy, aims to “press” on the cancer cells by starving them of their preferred fuels followed by the application of oxidative stressors as a “pulse” to kill the cancer cells. Currently research is testing the inclusion of the glycolytic inhibitor 2-DG with DON (6-Diazo-5-oxo-L-norleucine), HBOT, and a restricted ketogenic diet.

onenine

Preclinical Studies

07/09/2025

Other Projects of Interest

A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment

This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be

Clinical Trials

FMCT-ct1.

We are in the preliminary planning to fund a two-armed, phase 2 clinical trial testing the adjunctive efficacy of the

Preclinical Studies

FMCT-pc3.

We are funding research to test the preclinical efficacy of a special formulation of mebendazole designed to make the active